FDA PREEMPTION OF PROP. 65 DENTAL MERCURY RULES: CALIF. CONSIDERING APPEAL
This article was originally published in The Gray Sheet
Executive Summary
FDA PREEMPTION OF PROP. 65 DENTAL MERCURY RULES: CALIF. CONSIDERING APPEAL of a recent court ruling that FDA requirements for dental mercury preempt California's Proposition 65 warning requirements for the product. Judge Rudi Brewster of the U.S. District Court for the Southern District of Califomia found that "Proposition 65's warning requirements, when imposed on dental mercury or products containing dental mercury, are different from, or in addition to, specific [Food, Drug and Cosmetic Act Medical Device Amendments] requirements applicable to dental mercury or products containing dental mercury, and consequently are preempted." Prop. 65 requires warnings for dental mercury because the state has deemed it a reproductive toxicant.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.